Oral GLP-1 care requires choosing the exact product and approved purpose. Foundayo and Wegovy tablets offer adult weight-management options.
Call before traveling and name the exact service and location. Confirm the appointment, provider, records, tests, and medicine arrangements. A general walk-in visit does not guarantee a prescription, administration, specialist treatment, or a dietitian appointment that day.
Oral GLP-1 care requires choosing the exact product and approved purpose. Foundayo and Wegovy tablets offer adult weight-management options. Ozempic tablets and Rybelsus treat adult type 2 diabetes. Their dosing and eating instructions differ.
These medicines activate GLP-1 receptors, but they have different ingredients or absorption formulations. Foundayo can be taken with or without food. Oral semaglutide requires an empty stomach, limited water, and a wait before other intake.
Weight-management tablets are for qualifying adults after a safety review. Having PCOS or wanting to avoid injections does not alone establish eligibility. Diabetes tablets should not be described as approved obesity medicines.
Review your diagnosis, current medicine, other oral drugs, contraception, and morning routine. Choose the exact tablet and teach its instructions. Check insurance and pharmacy access separately from the visit. Switching from an injection or another tablet needs a prescriber’s plan, not a milligram conversion.
Bring your weight and treatment history, medicines and supplements, relevant glucose, kidney, and lipid results, and the exact product you have used before. Mention previous side effects, eye disease, eating difficulties, and pregnancy plans. If insurance denied treatment, bring the denial and plan details.
Review a personal or family history of medullary thyroid cancer, MEN 2, severe stomach-emptying problems, pancreatitis, gallbladder disease, allergies, and pregnancy plans before treatment. Nausea, vomiting, constipation, or diarrhea can occur. Persistent severe abdominal pain or inability to keep fluids down needs emergency department assessment now. Call 911 for breathing difficulty, a severe allergic reaction, loss of consciousness or unsafe travel. Tell the anesthesia team about treatment before a procedure. Do not combine GLP-1 medicines or change the dose yourself. Foundayo requires additional or non-oral contraception for 30 days after starting and each dose increase. Oral semaglutide products have their own pregnancy and breastfeeding instructions.
Review weight trend, appetite, food and fluid intake, bowel symptoms, and treatment tolerability. Check glucose and adjust other diabetes medicines with the prescriber when relevant. Agree on how to contact the team between visits and what to do if a refill is delayed. Continued treatment depends on benefit, safety, access, and your goals.
Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.
Nao Medical Long Island City: 30-07 36th Ave, Long Island City, NY 11106. Call +1-917-310-3371 to confirm the specific service, clinician and appointment before travelling.
Contact the clinic to confirm this service, the clinician and appointment preparation. General clinic hours may differ from service appointment times.
Confirm the current address, hours, and appointment arrangements with Nao Medical before traveling. Mention the specific location and oral glp-1 care requires choosing the exact product and approved purpose. Ask whether records, tests, prescription review, training, or administration must be arranged ahead of time.
Call before traveling to confirm the exact service and appointment. An evaluation may require records, tests, or a later treatment decision. A general walk-in appointment does not guarantee medication, an injection, or specialist care that day. Bring your weight and treatment history, medicines and supplements, relevant glucose, kidney, and lipid results, and the exact product you have used before. Mention previous side effects, eye disease, eating difficulties, and pregnancy plans. If insurance denied treatment, bring the denial and plan details.
Bring your weight and treatment history, medicines and supplements, relevant glucose, kidney, and lipid results, and the exact product you have used before. Mention previous side effects, eye disease, eating difficulties, and pregnancy plans. If insurance denied treatment, bring the denial and plan details.
Both contain semaglutide, but the tablet and injection have different doses, administration, and indications. Tablets have adult weight and qualifying cardiovascular uses. Injection also has specified pediatric obesity and MASH uses. They are not milligram-for-milligram substitutes.
Foundayo can be taken with or without food. Wegovy tablets and Ozempic tablets/Rybelsus require an empty stomach with no more than four ounces of water and a wait of at least 30 minutes before food, other drinks, or oral medicines. Follow the exact product’s instructions. Do not transfer fasting rules between brands.
Semaglutide activates GLP-1 receptors; tirzepatide activates GIP and GLP-1 receptors. Their diabetes and weight brands have different indications and instructions. Foundayo contains orforglipron, another GLP-1 medicine. Metformin acts differently. Choose the exact medicine for the clinical goal rather than treating them as interchangeable.
A switch needs review of the exact product, dose, time on treatment, response, side effects, nutrition, and access. A plateau alone does not mean you must change medicines. The prescriber sets a transition and titration plan. Do not overlap products or convert milligrams yourself.
As of October 9, 2026, Medicare’s GLP-1 Bridge includes Foundayo and Wegovy tablets for eligible adults with Part D coverage, with a $50 monthly copayment. It began July 1, 2026 and runs through December 31, 2027. Eligibility includes BMI 35 or higher. With BMI 30 or higher, qualifying conditions include heart failure with preserved ejection fraction, uncontrolled hypertension or stage 3a or later kidney disease. With BMI 27 or higher, they include prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease. People already receiving Part D-covered GLP-1s and those with type 2 diabetes, moderate-to-severe obstructive sleep apnea or noncirrhotic MASH with moderate-to-advanced fibrosis are excluded; their usual Part D benefits may apply instead. A prescription, lifestyle-program certification and required authorization are needed. Ask the prescriber and Medicare to check your eligibility. The copayment does not count toward the Part D deductible or out-of-pocket limit.
If you are vision-impaired or have some other impairment covered by the Americans with Disabilities Act or a similar law, and you wish to discuss potential accommodations related to using this website, please contact Sharad Suri at service@naomedical.com or by phone at (917) 633-1548 Extension 288. In our goal to answer your questions as quick as possible, we use the assistance of a large language model wherever applicable. If there are any errors or concerns, please bring it to our attention by emailing us.
Enter your phone number to begin scheduling your appointment.
You will be redirected to complete the appointment booking. Next: Book Appointment
Nao Medical will never sell your information to a third party.
Choose urgent care for a non-emergency illness or minor injury. For preventive visits and ongoing management, explore primary care at this location.
Visiting later? Review after-hours options and confirm clinic hours before traveling. For a life-threatening emergency, call 911.
(917) 310-3371
Facebook
Instagram
Twitter
LinkedIn
